EACS2023: 977 A shot in the dark: a review one year on after initiation of injectable HIV Treatment in a UK HIV outpatient clinic J. Roberts , L. Paul , C. Richardson , J. Jaquiss , A. Clarke University Hospitals Sussex NHS Trust, Lawson Unit, Brighton, United Kingdom, University Hospitals Sussex NHS Trust/ Brighton and Sussex Medical School, Clinical Research Facility -Sussex House, Brighton, United Kingdom General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: In Jan 2022 Long-Acting Injectable HIV Treatment (LAI) was approved in England using Cabotegravir and Rilpivirine two monthly injections. We evaluate the implementation, eligibility, and uptake of LAI in our clinic. Method: We established a multidisciplinary working group to implement a new LAI service. Referrals were reviewed weekly for eligibility as per current British HIV Association (BHIVA) guidance. Demographics, eligibility criteria, antiretroviral therapy (ARV) and outcomes were collected from electronic patient records from beginning March 2022- end June 2023. Results: Results 160/2303 (7%) patients were referred for LAI consideration. 51/160 (32%) were ineligible: 24/51 had resistance/unplanned ARV treatment stops; 5/51 required treatment to cover hepatitis B; 3/51 subtype A1/6 plus BMI>30; 5/51 interacting concomitant medication; 10/51 HIV viraemia; 2/51 were deemed unlikely to commit to schedule, 1/51 INSTIs intolerance, 1/51 died unrelated to HIV. 57/160 (36%) eligible patients subsequently declined LAI when offered, see Table 1. Table 1. The most frequent reasons for declining injectables following confirmation of eligibility. 51/160 (32%) initiated on the injectables pathway, 16/51 excluded from this data as enrolled in a LAI trial. 2/51 discontinued at oral lead in stage due to side effects. Of the 33/51 patients started LAI within the clinic 97% identify as cis-male, 91% are GBMSM, 67% of white UK, median age 46yrs (range 3464yrs). The majority of these were taking a single tablet regimen at switch (table 2). All are virally suppressed. Table 2: Previous ARV pill count of those on LAI Regimen Number 1 tablet 23 (70%) 2 tablets 9 (27%) 3 tablets 1 (3%) Conclusions: A structured multidisciplinary approach, adequate patient information and thorough eligibility checking were all crucial in establishing our LAI service. Of the referred patients, 1/3 were ineligible 1/3 declined and 1/3 proceeded to LAI. All those on LAI remain virally supressed. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.).: Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 2 1 2 185
RkJQdWJsaXNoZXIy Mzc2ODc=